Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eileen Dolan

Showing results (11-20 of 188) with videos related to

Pageof 19
Sort By:
Current Opinion in Oncology|November 19, 2003
Temozolomide: realizing the promise and potentialR Nagasubramanian, M Eileen Dolan
Journal of the National Cancer Institute|January 5, 2002
Silence is golden: gene hypermethylation and survival in large-cell lymphomaM Eileen Dolan, Richard L Schilsky
Pharmacogenomics|March 31, 2010
Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020R Stephanie Huang, M Eileen Dolan
Cancer Treatment Reviews|November 7, 2006
Molecular mechanisms of resistance and toxicity associated with platinating agentsCara A Rabik, M Eileen Dolan
Pharmacogenomics|July 15, 2005
Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studiesSunita J Shukla, M Eileen Dolan
Pharmacogenomics|December 20, 2011
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translationHeather E Wheeler, M Eileen Dolan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2009
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapyPeter H O'Donnell, M Eileen Dolan
Pharmacogenomics|April 6, 2013
Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes?Amy L Stark, M Eileen Dolan
Pharmacogenomics|October 11, 2007
Identifying genetic variants that contribute to chemotherapy-induced cytotoxicityChristine M Hartford, M Eileen Dolan
JAMA|July 21, 2011
Genetics and variable drug responseRussell A Wilke, M Eileen Dolan
Pageof 19

Showing results (11-20 of 188) with videos related to

Sort By:
Pageof 19
Current Opinion in Oncology|November 19, 2003
Temozolomide: realizing the promise and potentialR Nagasubramanian, M Eileen Dolan
Journal of the National Cancer Institute|January 5, 2002
Silence is golden: gene hypermethylation and survival in large-cell lymphomaM Eileen Dolan, Richard L Schilsky
Pharmacogenomics|March 31, 2010
Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020R Stephanie Huang, M Eileen Dolan
Cancer Treatment Reviews|November 7, 2006
Molecular mechanisms of resistance and toxicity associated with platinating agentsCara A Rabik, M Eileen Dolan
Pharmacogenomics|July 15, 2005
Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studiesSunita J Shukla, M Eileen Dolan
Pharmacogenomics|December 20, 2011
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translationHeather E Wheeler, M Eileen Dolan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2009
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapyPeter H O'Donnell, M Eileen Dolan
Pharmacogenomics|April 6, 2013
Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes?Amy L Stark, M Eileen Dolan
Pharmacogenomics|October 11, 2007
Identifying genetic variants that contribute to chemotherapy-induced cytotoxicityChristine M Hartford, M Eileen Dolan
JAMA|July 21, 2011
Genetics and variable drug responseRussell A Wilke, M Eileen Dolan
Pageof 19